Filing Flows › Tarsus Pharmaceuticals (TARS) › Q3 2026 › vs Q3 2025
Tarsus Pharmaceuticals (TARS) Q3 2026 vs Q3 2025 (year over year)
Tarsus Pharmaceuticals's revenue rose $75.9M (+64%) from $119M in Q3 2025 to $195M in Q3 2026.
Tarsus Pharmaceuticals, Q3 2026: revenue $195M (+64% year over year), operating margin -340.3%, net loss $668M, operating cash flow −$6.0M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $195M | $119M | $75.9M | +64% |
| Net loss | $668M | $12.6M | $656M | 53× |
| Costs & expenses | $863M | $133M | $730M | +548% |
| Operating costs | $857M | $133M | $723M | +543% |
| Interest & other, net | $1.6M | −$1.9M | $3.5M | — |
| Income tax | $4.6M | $0 | $4.6M | — |
| Cost of revenue | $13.9M | $8.3M | $5.6M | +67% |
| Research & development | $44.2M | $16.3M | $27.9M | +171% |
| SG&A | $168M | $109M | $59.4M | +55% |
| Operating cash sources | $668M | $12.6M | $656M | 53× |
| Depreciation & amortization | $1.0M | $400K | $600K | +150% |
| Share-based compensation | $27.2M | $12.2M | $15.0M | +122% |
| Working capital & other | $634M | $18.2M | $616M | 35× |
| Cash used in operations | $6.0M | −$18.3M | $24.3M | — |
| Net loss absorbed | $668M | $12.6M | $656M | 53× |
Questions
How much did Tarsus Pharmaceuticals's revenue grow year over year in Q3 2026?
Tarsus Pharmaceuticals's revenue rose $75.9M (+64%) from $119M in Q3 2025 to $195M in Q3 2026.